Related Experiment Video
Updated: Mar 5, 2026
Noninvasive, High-throughput Determination of Sleep Duration in Rodents
Published on: April 18, 2018
Fatal Familial Insomnia: Clinical Aspects and Molecular Alterations
Franc Llorens1,2, Juan-José Zarranz3, Andre Fischer4
1Department of Neurology, Clinical Dementia Center, University Medical Center, Georg-August University, Robert Koch Strasse 40, Göttingen, Germany. Franc.llorens@gmail.com.
Purpose Of Review:
Fatal familiar insomnia (FFI) is an autosomal dominant inherited prion disease caused by D178N mutation in the prion protein gene (PRNP D178N) accompanied by the presence of a methionine at the codon 129 polymorphic site on the mutated allele. FFI is characterized by severe sleep disorder, dysautonomia, motor signs and abnormal behaviour together with primary atrophy of selected thalamic nuclei and inferior olives, and expansion to other brain regions with disease progression. This article reviews recent research on the clinical and molecular aspects of the disease.
Recent Findings:
New clinical and biomarker tools have been implemented in order to assist in the diagnosis of the disease. In addition, the generation of mouse models, the availability of 'omics' data in brain tissue and the use of new seeding techniques shed light on the molecular events in FFI pathogenesis. Biochemical studies in human samples also reveal that neuropathological alterations in vulnerable brain regions underlie severe impairment in key cellular processes such as mitochondrial and protein synthesis machinery. Although the development of a therapy is still a major challenge, recent findings represent a step toward understanding of the clinical and molecular aspects of FFI.
Insights
Fatal familiar insomnia (FFI) is a rare prion disease linked to the PRNP D178N mutation. Recent research advances diagnostic tools and reveals molecular insights into FFI pathogenesis and cellular impairments.
Area of Science:
- Neuroscience
- Genetics
- Pathology
Background:
- Fatal familiar insomnia (FFI) is an autosomal dominant prion disease.
- It is caused by the PRNP D178N mutation with methionine at codon 129.
- FFI presents with severe sleep disorders, dysautonomia, motor signs, and behavioral changes, alongside thalamic and olivary atrophy.
Purpose of the Study:
- To review recent clinical and molecular research on Fatal Familiar Insomnia.
- To highlight advancements in understanding FFI pathogenesis and diagnosis.
Main Methods:
- Implementation of new clinical and biomarker tools for diagnosis.
- Generation of mouse models for FFI.
- Utilizing 'omics' data and seeding techniques to study molecular events.
- Biochemical studies on human brain tissue to identify neuropathological alterations.
Main Results:
- New diagnostic tools are aiding in FFI identification.
- Mouse models and 'omics' data provide insights into FFI molecular pathogenesis.
- Biochemical analyses reveal impaired mitochondrial and protein synthesis machinery in affected brain regions.
Conclusions:
- Recent findings offer a deeper understanding of FFI's clinical and molecular aspects.
- While therapy development remains challenging, research progresses in understanding the disease.
- Advancements in diagnostics and molecular insights mark significant steps in FFI research.
More Related Videos
Related Concept Videos
01:07Narcolepsy
01:27Insomnia
Multiple factors contribute...
01:19Management of Insomnia
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
02:19Circadian Rhythms and Gene Regulation
01:24Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge: